Bio-availability and dissolution of three phenytoin preparations for children

Area of Science:

• Pharmacokinetics
• Clinical Pharmacy
• Pediatric Neurology

Background:

• Phenytoin is a common antiepileptic drug used to manage seizures.
• Variations in bioavailability between different phenytoin formulations may impact therapeutic outcomes.
• Ensuring consistent drug levels is crucial for effective epilepsy treatment in children.

Purpose of the Study:

• To compare the bioavailability of three different brands of phenytoin (50mg capsules/tablets) in pediatric patients.
• To assess the impact of different phenytoin brands on serum drug levels and seizure frequency.
• To provide evidence-based recommendations for phenytoin brand selection in pediatric epilepsy management.

Main Methods:

• A bioavailability study involving 30 children diagnosed with tonic-clonic or complex partial seizures.
• Serum phenytoin levels were monitored over time for each drug preparation.
• In vitro dissolution testing was performed on the three phenytoin brands.

Main Results:

• Phenytoin capsules (Parke Davis) and tablets (Boots) demonstrated significantly higher serum-level profiles compared to phenytoin tablets (Evans).
• No significant differences in seizure frequencies were observed across the three phenytoin brands.
• In vitro dissolution profiles varied among the tested phenytoin preparations, correlating with in vivo bioavailability.

Conclusions:

• The bioavailability of phenytoin varies significantly between different manufacturers' brands.
• Consistent use of a single manufacturer's brand of phenytoin is recommended for pediatric patients to maintain stable serum levels and optimize seizure control.
• Further research into formulation-specific bioavailability is warranted for antiepileptic drug therapy.